[Management of ICANS in Patient Treated with Anti-CD19 CAR T-Cell Therapy]
{{output}}
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has been established as a standard of care in selected patients with relapsed or refractory large B-cell lymphoma (LBCL). Unlike conventional cytotoxic chemotherapy, CAR T-cell therapy has unique immune-... ...
